Kodiak Sciences Inc.
Zenkuda (tarcocimab tedromer)
diabetic retinopathy
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Zenkuda (tarcocimab tedromer) for diabetic retinopathy is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Based on the strong efficacy, safety and durability data demonstrated in the GLOW2 study, Zenkuda now has a multi-indication BLA-ready profile, and Kodiak intends to accelerate the BLA submission timeline.”